EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico

Yanet Ventura-Enríquez, Evelyn Cortina-De la Rosa, Elizabeth Díaz-Padilla, Sandra Murrieta, Silvia Segundo-Martínez, Verónica Fernández-Sánchez iD, Cruz Vargas-De-León iD

Viruses · 2024

DOI: 10.3390/v16040551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Yanet Ventura-Enríquez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Banco de Sangre, Centro Médico Naval (CEMENAV), Coyoacán, Ciudad de México 04470, Mexico. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19, Immunization, Secondary, Antibodies, Viral. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CEMENAV (Centro Medico Naval, Naval Medical Center).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Booster doses of the SARS-CoV-2 vaccine have been recommended to improve and prolong immunity, address waning immunity over time, and contribute to the control of the COVID-19 pandemic. A heterologous booster vaccine strategy may offer advantages over a homologous approach. To compare the immunogenicity of two doses of BNT162b2 mRNA COVID-19 vaccine with a ChAdOx1-S booster dose, immunoglobulin G (IgG) anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibody titers (Ab) were compared over 1 year and post-booster vaccination. Results showed that, at 3- to 9-month assessments in vaccinated subjects, an-ti-N Ab were undetectable in participants with no history of COVID-19. In contrast, anti-S Ab measurements were lower than those with COVID-19, and a decrease was observed during the 9 months of observation. After booster vaccination, no differences were found in anti-S between participants who reported a history of COVID-19 and those who did not. Anti-S levels were higher after booster vaccination measurement vs. at 9 months in participants with COVID-19 and without COVID-19, i.e., independent of an infection history. Vaccine administration elicited a response of higher anti-S IgG levels in those infected before vaccination, although levels decreased during the first nine months. IgG anti-N titers were higher in participants with a history of declared infection and who were asymptomatic. The ChAdOx1-S booster increased anti-S Ab levels in participants regardless of whether they had been infected or not to a significantly higher value than with the first two vaccines. These findings underscore the importance of booster vaccination in eliciting a robust and sustained immune response against COVID-19, regardless of the prior infection status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineCOVID-19Immunization, SecondaryAntibodies, ViralSARS-CoV-2COVID-19 VaccinesMilitary PersonnelImmunoglobulin GImmunogenicity, VaccineHumansMaleAdultMexicoFemaleSpike Glycoprotein, CoronavirusChAdOx1 nCoV-19Young AdultVaccinationMiddle Aged

Stichwörter der Autor:innen

COVID-19SARS-COV-immunityantibody IgGspikevaccine

Substanzen

BNT162 VaccineAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, CoronavirusChAdOx1 nCoV-19spike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Banco de Sangre, Centro Médico Naval (CEMENAV), Coyoacán, Ciudad de México 04470, Mexico.
  • Departamento de Hematología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico.
  • Facultad de Química, Universidad Nacional Autónoma de México (UNAM), Ciudad de México 04510, Mexico.
  • Facultad de Estudios Superiores Iztacala (FES-Iztacala), Universidad Nacional Autónoma de México (UNAM), Ciudad de México 54090, Mexico.
  • División de Investigación, Hospital Juárez de México, Ciudad de México 07760, Mexico.
  • Laboratorio de Modelación Bioestadística Para la Salud, Sección de Estudios de Investigación y Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.

ORCID-Profile: Verónica Fernández-Sánchez, Cruz Vargas-De-León

Förderung

  • CEMENAV (Centro Medico Naval, Naval Medical Center)

Zitieren

APA

Ventura-Enríquez, Y., Cortina-De la Rosa, E., Díaz-Padilla, E., Murrieta, S., Segundo-Martínez, S., Fernández-Sánchez, V., & Vargas-De-León, C. (2024). Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico. Viruses. https://doi.org/10.3390/v16040551

Vancouver

Ventura-Enríquez Y, Cortina-De la Rosa E, Díaz-Padilla E, Murrieta S, Segundo-Martínez S, Fernández-Sánchez V, et al. Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico. Viruses. 2024. doi:10.3390/v16040551

BibTeX
@article{VenturaEnrquez2024,
  author = {Ventura-Enríquez, Yanet and Cortina-De la Rosa, Evelyn and Díaz-Padilla, Elizabeth and Murrieta, Sandra and Segundo-Martínez, Silvia and Fernández-Sánchez, Verónica and Vargas-De-León, Cruz},
  title = {Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16040551}
}
Kostenlos starten →